Research programme: anticancer monoclonal antibodies - MabVax/MSKCC

Drug Profile

Research programme: anticancer monoclonal antibodies - MabVax/MSKCC

Alternative Names: 1B7; 1B7/31F; Anti-GD2 antibodies - MabVax Therapeutics; HuMab-1B7; HuMab-31F9; HuMab-Tn; r5B1

Latest Information Update: 11 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MabVax Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action GD2 ganglioside inhibitors; Tumour-associated carbohydrate antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 09 Jul 2018 Monoclonal antibodies targetting glycans (Thomsen-nouveau (Tn) and the sialyl Tn (sTn) carbohydrate antigens) licensed to Boehringer ingelheim
  • 17 May 2018 The United States Patent and Trademark Office grants a patent for fully human anti-GD2 antibodies expressed on Sarcoma, Melanoma and Neuroblastoma
  • 06 Nov 2017 HuMab-Tn fully -human monoclonal antibodies is still in preclinical studies for Cancer in USA (Mabvax Therapeutics pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top